Increased liver oxidative stress and altered PUFA metabolism precede development of non-alcoholic steatohepatitis in SREBP-1a transgenic spontaneously hypertensive rats with genetic predisposition to hepatic steatosis

. 2010 Feb ; 335 (1-2) : 119-25. [epub] 20090912

Jazyk angličtina Země Nizozemsko Médium print-electronic

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid19756959

Grantová podpora
HL35018 NHLBI NIH HHS - United States
HL56028 NHLBI NIH HHS - United States
HL63709 NHLBI NIH HHS - United States

The temporal relationship of hepatic steatosis and changes in liver oxidative stress and fatty acid (FA) composition to the development of non-alcoholic steatohepatitis (NASH) remain to be clearly defined. Recently, we developed an experimental model of hepatic steatosis and NASH, the transgenic spontaneously hypertensive rat (SHR) that overexpresses a dominant positive form of the human SREBP-1a isoform in the liver. These rats are genetically predisposed to hepatic steatosis at a young age that ultimately progresses to NASH in older animals. Young transgenic SHR versus SHR controls exhibited simple hepatic steatosis which was associated with significantly increased hepatic levels of oxidative stress markers, conjugated dienes, and TBARS, with decreased levels of antioxidative enzymes and glutathione and lower concentrations of plasma alpha- and gamma-tocopherol. Transgenic rats exhibited increased plasma levels of saturated FA, decreased levels of n-3 and n-6 polyunsaturated FA (PUFA), and increased n-6/n-3 PUFA ratios. These results are consistent with the hypothesis that excess fat accumulation in the liver in association with increased oxidative stress and disturbances in the metabolism of saturated and unsaturated fatty acids may precede and contribute to the primary pathogenesis of NASH.

Zobrazit více v PubMed

World J Gastroenterol. 2008 Jan 14;14(2):185-92 PubMed

Clin Chim Acta. 2005 May;355(1-2):105-11 PubMed

Pediatr Res. 2005 Mar;57(3):445-52 PubMed

J Biol Chem. 1957 May;226(1):497-509 PubMed

J Nutr Biochem. 2008 Sep;19(9):567-76 PubMed

Hepatology. 1990 Nov;12(5):1106-10 PubMed

Obesity (Silver Spring). 2007 Jan;15(1):24-31 PubMed

J Investig Med. 2004 Dec;52(8):506-14 PubMed

Diabetologia. 2008 Feb;51(2):328-35 PubMed

Trends Mol Med. 2006 Dec;12(12):555-8 PubMed

Vet Pathol. 1998 May;35(3):227-9 PubMed

J Clin Invest. 1985 Aug;76(2):517-27 PubMed

J Nutr. 2000 Jun;130(6):1561-5 PubMed

World J Gastroenterol. 2008 Apr 28;14(16):2474-86 PubMed

J Hepatol. 2008 Feb;48(2):300-7 PubMed

Int J Clin Pract. 2005 Mar;59(3):318-23 PubMed

Biochimie. 2004 Nov;86(11):799-806 PubMed

Gastroenterology. 1998 Apr;114(4):842-5 PubMed

Ann N Y Acad Sci. 2002 Jun;967:446-53 PubMed

Hypertension. 2005 May;45(5):1004-11 PubMed

Lipids. 2003 Jul;38(7):733-42 PubMed

Anal Biochem. 1968 Oct 24;25(1):192-205 PubMed

Clin Sci (Lond). 2004 Jun;106(6):635-43 PubMed

Liver Int. 2005 Oct;25(5):946-53 PubMed

J Lab Clin Med. 1976 Jun;87(6):1057-64 PubMed

J Nutr. 2005 Nov;135(11):2634-8 PubMed

J Clin Invest. 1988 Mar;81(3):720-9 PubMed

Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):327-35 PubMed

J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10 PubMed

J Nutr Sci Vitaminol (Tokyo). 2001 Apr;47(2):102-7 PubMed

Methods Enzymol. 1986;123:215-9 PubMed

Methods Enzymol. 1984;105:121-6 PubMed

Am J Clin Nutr. 2006 Dec;84(6):1290-8 PubMed

Ann Clin Lab Sci. 2004 Winter;34(1):57-62 PubMed

Clin Sci (Lond). 2004 Mar;106(3):261-8 PubMed

Ann N Y Acad Sci. 2002 Jun;967:183-95 PubMed

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

Beneficial Effect of Fenofibrate in Combination with Silymarin on Parameters of Hereditary Hypertriglyceridemia-Induced Disorders in an Animal Model of Metabolic Syndrome

. 2025 Jan 16 ; 13 (1) : . [epub] 20250116

The Ameliorating Effects of n-3 Polyunsaturated Fatty Acids on Liver Steatosis Induced by a High-Fat Methionine Choline-Deficient Diet in Mice

. 2023 Dec 07 ; 24 (24) : . [epub] 20231207

The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome

. 2021 Mar 17 ; 70 (1) : 33-43. [epub] 20210114

Heterozygous connexin 50 mutation affects metabolic syndrome attributes in spontaneously hypertensive rat

. 2016 Nov 21 ; 15 (1) : 199. [epub] 20161121

Experimental models of non-alcoholic fatty liver disease in rats

. 2014 Jul 14 ; 20 (26) : 8364-76.

Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats

. 2014 ; 9 (7) : e101906. [epub] 20140710

Folate deficiency is associated with oxidative stress, increased blood pressure, and insulin resistance in spontaneously hypertensive rats

. 2013 Jan ; 26 (1) : 135-40.

CD36 overexpression predisposes to arrhythmias but reduces infarct size in spontaneously hypertensive rats: gene expression profile analysis

. 2012 Feb 01 ; 44 (2) : 173-82. [epub] 20111129

Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome

. 2011 Apr ; 57 (4) : 731-7. [epub] 20110228

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...